Eli Lilly and Company (LLY)
| Market Cap | 312.22B |
| Revenue (ttm) | 29.32B |
| Net Income (ttm) | 6.13B |
| Shares Out | 950.16M |
| EPS (ttm) | 6.73 |
| PE Ratio | 48.83 |
| Forward PE | 39.06 |
| Dividend | $3.66 (1.11%) |
| Ex-Dividend Date | Aug 12, 2022 |
| Volume | 980,710 |
| Open | 327.25 |
| Previous Close | 330.15 |
| Day's Range | 326.24 - 330.42 |
| 52-Week Range | 220.20 - 332.74 |
| Beta | 0.40 |
| Analysts | Buy |
| Price Target | 327.14 (-0.4%) |
| Earnings Date | Aug 2, 2022 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal... [Read more...]
Financial Performance
In 2021, LLY's revenue was $28.32 billion, an increase of 15.40% compared to the previous year's $24.54 billion. Earnings were $5.58 billion, a decrease of -9.88%.
Financial StatementsAnalyst Forecast
According to 31 analysts, the average rating for LLY stock is "Buy." The 12-month stock price forecast is 327.14, which is a decrease of -0.44% from the latest price.
News
As Markets Churn, These 2 Stocks Just Hit All-Time Highs
You can find winners even in today's stock market.
What Bear Market? These 2 Stocks Are Killing It.
What else do these companies have in store?
These 3 Stocks Might (Still) Be a Little Too Expensive
Yes, valuations still matter, and it may take further time for them to reach appropriate levels.
Eli Lilly to supply another 150,000 doses of COVID treatment to the government
Eli Lilly & Co. LLY, -2.95% said Wednesday that it will supply the U.S. government with an additional 150,000 doses of its COVID treatment bebtelovimab for about $275 million. Delivery of the doses will...
Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-1...
Bebtelovimab continues to maintain neutralization against all known variants of interest and concern INDIANAPOLIS , June 29, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a modi...
All-time highs for pharma stocks: Names to trade now
Big pharma surges, and here are the names to trade. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Dan Nathan, Courtney Garcia and Karen Finerman.
Lilly Declares Third-Quarter 2022 Dividend
INDIANAPOLIS , June 27, 2022 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2022 of $0.98 per share on outstanding common st...
Why Eli Lilly & Co could be a recession-proof stock
With inflation raging and the Federal Reserve (Fed) waging an epic battle against it, a recession seems on the horizon.
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with C...
SAN FRANCISCO and SUZHOU, China, June 26, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...
Stocks Rebound Strongly; Exxon Mobil, Dollar General, Eli Lilly In Focus | Stock Market Today
Nice session, but market rally isn't confirmed yet. Get more IBD by subscribing to our channel: https://bit.ly/3OqppAs Visit our website: investors.com Like us on Facebook: https://www.facebook.com/inve...
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with C...
SAN FRANCISCO, INDIANAPOLIS and SUZHOU, China, June 20, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
Why Eli Lilly's Immunology Prospects Look Promising
Uplifting news turns the tide in immunology.
Roche Alzheimer's Candidate Failure Hurts Lilly, Biogen
Eli Lilly (LLY) and Biogen's (BIIB) Alzheimer's candidates, anti-amyloid beta antibodies, are in late-stage development and are expected to be launched in a few months.
Lilly (LLY), Incyte's Olumiant Gets FDA Nod for Alopecia Areata
Lilly (LLY) and Incyte's Olumiant is the first-ever FDA-approved systemic treatment for alopecia areata patients.
FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Al...
INDIANAPOLIS, June 13, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitini...
Final Trades: ChargePoint, Eli Lilly, Sabra Health Care & more
The "Halftime Report" traders give their top picks to watch for the second half.
Stock Market Falls, Oil Prices, Bond Yields Rise; United Therapeutics, Eli Lilly, Vertex Hold Up
Higher volume resulted in a distribution day for the indexes. Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists, investing data, stock market re...
Lilly (LLY) Eczema Candidate Keeps Skin Clearance for One Year
Data from late-stage studies conducted by Eli Lilly (LLY) shows that its atopic dermatitis drug maintained improvement in skin clearance and itch relief in 8 of 10 patients for a one-year treatment.
Eli Lilly weight loss drug for type-2 diabetes approved by the FDA
Yahoo Finance senior health reporter Anjalee Khemlani details Eli Lilly's type-2 diabetes drug approval by the FDA for use as a weight loss drug.
Whistleblower sues Eli Lilly over drug manufacturing problems
(Reuters) -A former human resources officer at Eli Lilly and Co sued the drugmaker on Monday, alleging she was terminated after pointing out poor manufacturing practices and data falsification involving...
Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy...
80% of lebrikizumab responders maintained improvements in skin clearance and disease severity at 52 weeks; lasting improvements in itch were also observed Data supported both once every two week and onc...
New analyses of Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the A...
Mounjaro led to significantly greater fat mass reductions compared to placebo and to injectable semaglutide 1 mg in adults with type 2 diabetes in mechanism of action study Exploratory analysis showed t...